Drugs / CellProtect
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04558931 | Jun 2021 → Dec 2027 expected | plasma cell myeloma | Karolinska Institutet | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CellProtect | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04558931 ↗ |
| Modality | Cell therapy | “In vitro expanded and activated autologous NK cells” NCT04558931 ↗ |
| Route | Intravenous | “CellProtect will be given IV infusion” NCT04558931 ↗ |